CN114848673A - 血小板或抑制线粒体活性的血小板在制备抑癌制剂中的应用 - Google Patents
血小板或抑制线粒体活性的血小板在制备抑癌制剂中的应用 Download PDFInfo
- Publication number
- CN114848673A CN114848673A CN202210570219.XA CN202210570219A CN114848673A CN 114848673 A CN114848673 A CN 114848673A CN 202210570219 A CN202210570219 A CN 202210570219A CN 114848673 A CN114848673 A CN 114848673A
- Authority
- CN
- China
- Prior art keywords
- platelets
- inhibiting
- platelet
- blood platelet
- mitochondrial activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 22
- 230000002438 mitochondrial effect Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 210000001772 blood platelet Anatomy 0.000 title claims description 50
- 239000002246 antineoplastic agent Substances 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 21
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 13
- 206010027476 Metastases Diseases 0.000 claims abstract description 7
- 230000009401 metastasis Effects 0.000 claims abstract description 7
- 230000012010 growth Effects 0.000 claims abstract description 4
- 210000003470 mitochondria Anatomy 0.000 claims abstract description 4
- 230000001093 anti-cancer Effects 0.000 claims abstract 2
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 claims description 6
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 claims description 6
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 claims description 6
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 claims description 6
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 claims description 6
- 229930191479 oligomycin Natural products 0.000 claims description 6
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 claims description 6
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 claims description 6
- 229940080817 rotenone Drugs 0.000 claims description 6
- 229930182536 Antimycin Natural products 0.000 claims description 3
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 claims description 3
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 claims description 3
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 claims description 3
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 claims description 3
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 239000003124 biologic agent Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000012292 cell migration Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及血小板在制备抑癌制剂中的应用；本发明还涉及抑制线粒体活性的血小板在制备抑癌制剂中的应用；本发明的血小板或抑制线粒体活性的血小板具有抑制癌细胞生长或/和转移的作用。
Description
技术领域
本发明涉及生物医药技术领域，尤其涉及血小板或抑制线粒体活性的血小板在制备抑癌制剂中的应用。
背景技术
血小板是从骨髓成熟的巨核细胞胞浆裂解脱落下来的小块胞质，对机体的止血功能极为重要。在肿瘤进展过程中，血小板的数目呈现出不同的变化。目前主要认为，血小板可能在肿瘤进展过程中增多，并作为肿瘤的燃料仓库，给肿瘤提供生长因子而发挥作用的。但也有研究发现，血小板会抑制肿瘤细胞的增殖。
血小板具有易于提取和改造等特点，因而亟需血小板或抑制线粒体活性的血小板在制备抑癌制剂中的应用。
发明内容
本发明的目的是针对现有技术中的不足，提供血小板或抑制线粒体活性的血小板在制备抑癌制剂中的应用。
为实现上述目的，本发明采取的技术方案是：
本发明的第一方面是提供血小板在制备抑癌制剂中的应用。
本发明的第二方面是提供抑制线粒体活性的血小板在制备抑癌制剂中的应用。
优选地，所述抑癌制剂为抑制癌细胞生长或/和转移的生物制剂。
优选地，所述癌细胞选自：肺癌细胞、乳腺癌细胞或骨癌细胞中的至少一种。
优选地，所述抑制线粒体活性的血小板为经寡霉素刺激的血小板。
优选地，所述寡霉素的浓度为3μmol/L-7μmol/L。
优选地，所述抑制线粒体活性的血小板为经鱼藤酮以及抗霉素A刺激的血小板。
优选地，所述鱼藤酮的浓度为1μmol/L-3μmol/L。
优选地，所述抗霉素A的浓度为1μmol/L-3μmol/L。
本发明采用以上技术方案，与现有技术相比，具有如下技术效果：
本发明的血小板或抑制线粒体活性的血小板具有抑制癌细胞生长或/和转移的作用。
附图说明
图1为本发明实施例3中CCK8-细胞增殖毒性检测细胞活性的结果图；
图2为本发明实施例3中细胞迁移实验检测细胞细胞转移能力的结果图。
具体实施方式
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动的前提下所获得的所有其他实施例，都属于本发明保护的范围。
需要说明的是，在不冲突的情况下，本发明中的实施例及实施例中的特征可以相互组合。
下面结合附图和具体实施例对本发明作进一步说明，但不作为本发明的限定。
实施例1分离纯化血小板
将获得的血液样品保存于肝素化台氏液(Tyrode's solution，134mM NaCl，2.9mMKCl，12mM NaHCO3，0.34mM Na2HPO4，20mM HEPES，pH 7.0，5mM葡萄糖和0.35％牛血清白蛋白)中，通过150g低速离心10分钟获得富血小板血浆，同时加入1％的前列腺素E2(PGE2)防止血小板激活；通过600g室温离心5分钟获得血小板沉淀；通过台氏液对血小板沉淀重悬，即得。
实施例2抑制线粒体活性
将实施例1所获得的血小板经5μmol/L的寡霉素(oligomycin)刺激3小时；或
将实施例1所获得的血小板经2μmol/L的鱼藤酮(rotenone)以及2μmol/L的抗霉素A(antimycin)刺激3小时；
即得抑制线粒体活性的血小板。
实施例3细胞实验
K7M2(小鼠骨肉瘤成骨细胞)分为三组，血小板组中加入数量为细胞数量100倍的血小板，抑制线粒体活性的血小板组中加入数量为细胞数量100倍的抑制线粒体活性的血小板，对照组中加入与血小板组或抑制线粒体活性的血小板组等量的PBS缓冲液；
通过CCK8-细胞增殖毒性检测细胞活性，结果如图1所示，血小板组较对照组而言，具有显著地(*p<0.05)抑制癌细胞生长的作用；抑制线粒体活性的血小板组较血小板组而言，具有较显著地(**p<0.01)抑制癌细胞生长的作用；
通过细胞迁移实验检测细胞转移能力，结果如图2所示，血小板组较对照组而言，具有极其显著地(***p<0.001)促进癌细胞转移的作用；抑制线粒体活性的血小板组较血小板组而言，具有极其显著地(***p<0.001)抑制癌细胞转移的作用。
综上所述，血小板或抑制线粒体活性的血小板具有抑制癌细胞生长或/和转移的作用。
以上所述仅为本发明较佳的实施例，并非因此限制本发明的实施方式及保护范围，对于本领域技术人员而言，应当能够意识到凡运用本发明说明书及图示内容所作出的等同替换和显而易见的变化所得到的方案，均应当包含在本发明的保护范围内。
Claims (9)
1.血小板在制备抑癌制剂中的应用。
2.抑制线粒体活性的血小板在制备抑癌制剂中的应用。
3.根据权利要求1或2所述的应用，其特征在于，所述抑癌制剂为抑制癌细胞生长或/和转移的生物制剂。
4.根据权利要求3所述的应用，其特征在于，所述癌细胞选自：肺癌细胞、乳腺癌细胞或骨癌细胞中的至少一种。
5.根据权利要求2所述的应用，其特征在于，所述抑制线粒体活性的血小板为经寡霉素刺激的血小板。
6.根据权利要求5所述的应用，其特征在于，所述寡霉素的浓度为3μmol/L-7μmol/L。
7.根据权利要求2所述的应用，其特征在于，所述抑制线粒体活性的血小板为经鱼藤酮以及抗霉素A刺激的血小板。
8.根据权利要求7所述的应用，其特征在于，所述鱼藤酮的浓度为1μmol/L-3μmol/L。
9.根据权利要求7所述的应用，其特征在于，所述抗霉素A的浓度为1μmol/L-3μmol/L。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210570219.XA CN114848673B (zh) | 2022-05-24 | 2022-05-24 | 血小板或抑制线粒体活性的血小板在制备抑癌制剂中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210570219.XA CN114848673B (zh) | 2022-05-24 | 2022-05-24 | 血小板或抑制线粒体活性的血小板在制备抑癌制剂中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114848673A true CN114848673A (zh) | 2022-08-05 |
| CN114848673B CN114848673B (zh) | 2024-06-28 |
Family
ID=82639141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210570219.XA Active CN114848673B (zh) | 2022-05-24 | 2022-05-24 | 血小板或抑制线粒体活性的血小板在制备抑癌制剂中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114848673B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130121979A1 (en) * | 2003-12-29 | 2013-05-16 | Allan Mishra | Method of treating cancer using platelet compositions |
| WO2018072673A1 (zh) * | 2016-10-17 | 2018-04-26 | 中国科学院动物研究所 | 一种调节血小板活性的药物、筛选方法及其用途 |
| US20190048317A1 (en) * | 2015-06-16 | 2019-02-14 | Kyoto University | Method for Producing Highly Functional Platelets |
| CN109689051A (zh) * | 2016-08-02 | 2019-04-26 | 蒙特利尔大学 | 线粒体活性抑制剂用于治疗不良预后急性髓性白血病的用途 |
| CN110279862A (zh) * | 2019-07-09 | 2019-09-27 | 上海市第六人民医院 | 一种抗癌组合物及其在制备治疗骨肉瘤的药物中的应用 |
-
2022
- 2022-05-24 CN CN202210570219.XA patent/CN114848673B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130121979A1 (en) * | 2003-12-29 | 2013-05-16 | Allan Mishra | Method of treating cancer using platelet compositions |
| US20190048317A1 (en) * | 2015-06-16 | 2019-02-14 | Kyoto University | Method for Producing Highly Functional Platelets |
| CN109689051A (zh) * | 2016-08-02 | 2019-04-26 | 蒙特利尔大学 | 线粒体活性抑制剂用于治疗不良预后急性髓性白血病的用途 |
| WO2018072673A1 (zh) * | 2016-10-17 | 2018-04-26 | 中国科学院动物研究所 | 一种调节血小板活性的药物、筛选方法及其用途 |
| CN110279862A (zh) * | 2019-07-09 | 2019-09-27 | 上海市第六人民医院 | 一种抗癌组合物及其在制备治疗骨肉瘤的药物中的应用 |
Non-Patent Citations (2)
| Title |
|---|
| LEA PLANTUREUX等: "The Interaction of Platelets with Colorectal Cancer Cells Inhibits Tumor Growth but Promotes Metastasis", CANCER RESEARCH, vol. 80, no. 2, pages 291 * |
| NARAYANASAMY BADRINATH等: "Mitochondria in cancer in the aspects of tumorigenesis and targeted therapy", CARCINOGENESIS, vol. 39, no. 12, pages 1419 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114848673B (zh) | 2024-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chinni et al. | CXCL12/CXCR4 signaling activates Akt‐1 and MMP‐9 expression in prostate cancer cells: the role of bone microenvironment‐associated CXCL12 | |
| Sheridan et al. | Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy | |
| Lee et al. | Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes | |
| Sorimachi et al. | Activation of macrophages by lactoferrin: secretion of TNF‐α, IL‐8 and NO | |
| Choi et al. | The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis | |
| Chalmers et al. | Pure red-cell anaemia in patients with thymic tumours | |
| Tan et al. | CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway | |
| LÓPEZ-LLUCH et al. | Protein kinase C-δ C2-like domain is a binding site for actin and enables actin redistribution in neutrophils | |
| Cervello et al. | Detection of vitellogenin in a subpopulation of sea urchin coelomocytes | |
| Wang et al. | Galectin-3 contributes to cisplatin-induced myeloid derived suppressor cells (MDSCs) recruitment in Lewis lung cancer-bearing mice | |
| US20160354401A1 (en) | Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells | |
| Clopath et al. | Growth promotion by homocysteic acid | |
| Komatsu et al. | Megakaryocytopoiesis in vitro of patients with essential thrombocythaemia: effect of plasma and serum on megakaryocyte colony formation | |
| Schmid et al. | Antineoplastic and toxic effects of Acinetobacter and Pseudomonas glutaminase-asparaginases | |
| CN114848673A (zh) | 血小板或抑制线粒体活性的血小板在制备抑癌制剂中的应用 | |
| Reusswig et al. | Efficiently restored thrombopoietin production by Ashwell‐Morell receptor and IL‐6R induced Janus Kinase 2/signal transducer and activator of transcription signaling early after partial hepatectomy | |
| Moore et al. | The transport and distribution of colloidal iron and its relation to the ultrastructure of the cell | |
| Cheung et al. | Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro | |
| Beguin et al. | Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation | |
| Reca et al. | The role of third complement component (C3) in homing of hematopoietic stem/progenitor cells into bone marrow | |
| Tschudy et al. | Immunosuppressive activity of succinylacetone | |
| Akagi et al. | The Critical Role of Src Homology Domain 2–Containing Tyrosine Phosphatase-1 in Recombinant Human Erythropoietin Hyporesponsive Anemia in Chronic Hemodialysis Patients | |
| Suega | Role of hepcidin in mechanism of anemia chronic disease patients | |
| Mizejewski | The Role of Ion Channels and Chemokines in Cancer Growth and Metastasis: A Proposed Mode of Action Using Peptides in Cancer Therapy | |
| CN114835776B (zh) | 一种靶向Smad4/PELO相互作用的抵抗肿瘤转移小分子多肽及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |